Published in Cell Stem Cell on May 06, 2011
Clonal evolution in cancer. Nature (2012) 11.07
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol (2015) 2.79
The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med (2013) 1.59
Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin. Br J Cancer (2012) 1.25
Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. Cancer Res (2013) 1.19
Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol (2014) 1.17
Laminin alpha 2 enables glioblastoma stem cell growth. Ann Neurol (2012) 1.13
Oncolytic viral therapy: targeting cancer stem cells. Oncolytic Virother (2014) 1.11
A novel probe for the non-invasive detection of tumor-associated inflammation. Oncoimmunology (2013) 1.05
Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. Genes Dis (2015) 1.05
CD163+ tumor-associated macrophages correlated with poor prognosis and cancer stem cells in oral squamous cell carcinoma. Biomed Res Int (2014) 1.04
Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche. Cancer Res (2013) 1.03
Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells (2015) 0.99
Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. J Clin Invest (2012) 0.98
Cancer stem cell contribution to glioblastoma invasiveness. Stem Cell Res Ther (2013) 0.98
The malignant social network: cell-cell adhesion and communication in cancer stem cells. Cell Adh Migr (2012) 0.96
Neural stem cell niches in health and diseases. Curr Pharm Des (2012) 0.91
Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade. Clin Cancer Res (2013) 0.91
Astrocytes promote glioma invasion via the gap junction protein connexin43. Oncogene (2015) 0.90
High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models. PLoS One (2013) 0.90
Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition. PLoS One (2012) 0.90
Cancer stem cell-specific scavenger receptor 36 drives glioblastoma progression. Stem Cells (2014) 0.89
Functional integration of acute myeloid leukemia into the vascular niche. Leukemia (2014) 0.89
Development of a Sox2 reporter system modeling cellular heterogeneity in glioma. Neuro Oncol (2014) 0.88
A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo. Cancer Res (2016) 0.87
Cancer Stem Cell Hierarchy in Glioblastoma Multiforme. Front Surg (2016) 0.87
HMMR maintains the stemness and tumorigenicity of glioblastoma stem-like cells. Cancer Res (2014) 0.86
Differential Effects of Cold Atmospheric Plasma in the Treatment of Malignant Glioma. PLoS One (2015) 0.84
Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling. Neuro Oncol (2014) 0.83
Bioengineering embryonic stem cell microenvironments for the study of breast cancer. Int J Mol Sci (2011) 0.81
Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR. Oncotarget (2016) 0.81
Extracellular Matrix Properties Regulate the Migratory Response of Glioblastoma Stem Cells in Three-Dimensional Culture. Tissue Eng Part A (2015) 0.81
Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance. Stem Cells Int (2016) 0.80
Glioma revisited: from neurogenesis and cancer stem cells to the epigenetic regulation of the niche. J Oncol (2012) 0.80
Enhancement of 5-aminolevulinic acid-based fluorescence detection of side population-defined glioma stem cells by iron chelation. Sci Rep (2017) 0.79
Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma. PLoS One (2014) 0.78
A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer. Oncotarget (2016) 0.78
Honokiol inhibits sphere formation and xenograft growth of oral cancer side population cells accompanied with JAK/STAT signaling pathway suppression and apoptosis induction. BMC Cancer (2016) 0.78
Expressions of glia maturation factor-β by tumor cells and endothelia correlate with neovascularization and poor prognosis in human glioma. Oncotarget (2016) 0.77
miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. Neuro Oncol (2016) 0.77
Cancer stem cell signaling pathways. Medicine (Baltimore) (2016) 0.77
Inactivation of p38 MAPK contributes to stem cell-like properties of non-small cell lung cancer. Oncotarget (2017) 0.75
Adult neurogenesis and glial oncogenesis: when the process fails. Biomed Res Int (2014) 0.75
Surgical delivery of drug releasing poly(lactic-co-glycolic acid)/poly(ethylene glycol) paste with in vivo effects against glioblastoma. Ann R Coll Surg Engl (2014) 0.75
Modulated DISP3/PTCHD2 expression influences neural stem cell fate decisions. Sci Rep (2017) 0.75
Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. Cell (2016) 0.75
Molecular and Microenvironmental Determinants of Glioma Stem-Like Cell Survival and Invasion. Front Oncol (2017) 0.75
S100A4 is a biomarker and regulator of glioma stem cells that is critical for mesenchymal transition in glioblastoma. Cancer Res (2017) 0.75
[Tumor pathophysiology]. Strahlenther Onkol (2012) 0.75
PNIPAAm-co-Jeffamine(®) (PNJ) scaffolds as in vitro models for niche enrichment of glioblastoma stem-like cells. Biomaterials (2017) 0.75
Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma. Oncogene (2017) 0.75
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
The increasing complexity of the cancer stem cell paradigm. Science (2009) 5.45
Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell (2010) 4.98
Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer (2007) 4.54
Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell (2010) 3.82
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 3.55
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev (2008) 3.50
NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells (2010) 3.42
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell (2010) 3.34
Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene (2009) 2.86
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res (2009) 2.74
A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain (2010) 2.49
Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia (2011) 2.32
Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89
Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ (2010) 1.79
Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci U S A (2009) 1.79
HIF-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc Natl Acad Sci U S A (2009) 1.46
Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem (2009) 1.33
Interaction of hypoxia-inducible factor-1α and Notch signaling regulates medulloblastoma precursor proliferation and fate. Stem Cells (2010) 1.15
Cancer: Tumour stem cells switch sides. Nature (2010) 0.98
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Embryonic stem cell-specific microRNAs promote induced pluripotency. Nat Biotechnol (2009) 5.14
Generation of induced pluripotent stem cells in the absence of drug selection. Cell Stem Cell (2007) 4.94
Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer (2007) 4.54
53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol (2002) 4.45
Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev (2002) 4.30
Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol (2008) 3.84
Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell (2010) 3.82
Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell (2004) 3.63
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 3.55
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell (2013) 3.32
Notch promotes radioresistance of glioma stem cells. Stem Cells (2010) 3.07
Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res (2008) 2.97
SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol Cell (2006) 2.75
Recent advances in the treatment of malignant astrocytoma. J Clin Oncol (2006) 2.55
HIF induces human embryonic stem cell markers in cancer cells. Cancer Res (2011) 2.46
c-Myc is required for maintenance of glioma cancer stem cells. PLoS One (2008) 2.41
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell (2013) 2.38
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol (2008) 2.32
Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci (2013) 2.30
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med (2012) 2.21
Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol (2003) 2.16
Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells (2008) 2.12
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell (2011) 2.04
Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells (2009) 1.97
Molecularly targeted therapy for malignant glioma. Cancer (2007) 1.96
53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res (2003) 1.87
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol (2005) 1.85
53BP1, an activator of ATM in response to DNA damage. DNA Repair (Amst) (2004) 1.84
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell (2011) 1.77
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog (2007) 1.74
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther (2005) 1.66
Biology of glioma cancer stem cells. Mol Cells (2009) 1.64
Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia (2011) 1.63
Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J (2004) 1.63
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res (2006) 1.63
Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol (2010) 1.60
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol (2010) 1.59
The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chains. Oncogene (2003) 1.55
Informed consent in pediatric surgery: Do parents understand the risks? Arch Otolaryngol Head Neck Surg (2010) 1.55
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol (2009) 1.53
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol (2002) 1.50
Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells. Nat Cell Biol (2011) 1.49
New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther (2006) 1.47
Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun (2011) 1.39
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res (2008) 1.35
SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther (2004) 1.35
Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem (2009) 1.33
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res (2004) 1.33
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol (2002) 1.32
Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol (2010) 1.32
MET signaling regulates glioblastoma stem cells. Cancer Res (2012) 1.29
Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One (2011) 1.29
Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci (2008) 1.28
Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol (2010) 1.27
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol (2010) 1.26
Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med (2013) 1.21
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer (2005) 1.21
Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasiveness. Cancer Res (2009) 1.18
Valosin-containing protein phosphorylation at Ser784 in response to DNA damage. Cancer Res (2005) 1.16
ATM signaling and 53BP1. Radiother Oncol (2005) 1.15
Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev (2012) 1.15
Laminin alpha 2 enables glioblastoma stem cell growth. Ann Neurol (2012) 1.13
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol (2006) 1.12
L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J (2011) 1.10
Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. Cancer Res (2005) 1.10
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol (2007) 1.10
Diagnosis and treatment of high-grade astrocytoma. Neurol Clin (2007) 1.08
β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res (2013) 1.08
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer (2005) 1.07
miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A (2013) 1.06
Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. Endocr Relat Cancer (2013) 1.06
EGFR mutations and sensitivity to gefitinib. N Engl J Med (2004) 1.05
The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells. Stem Cells (2014) 1.05
Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem (2004) 1.04
Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance. Genes Cancer (2010) 1.03
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol (2011) 1.02
The evolving landscape of glioblastoma stem cells. Curr Opin Neurol (2013) 1.02
The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol (2008) 1.01
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol (2008) 0.99
Chemokine CXCL12 in neurodegenerative diseases: an SOS signal for stem cell-based repair. Trends Neurosci (2012) 0.99
Tumor cells upregulate normoxic HIF-1α in response to doxorubicin. Cancer Res (2013) 0.99
The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol Cancer Ther (2007) 0.98
The Rho guanine nucleotide exchange factor AKAP13 (BRX) is essential for cardiac development in mice. J Biol Chem (2010) 0.97
Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol (2008) 0.96
New approaches to primary brain tumor treatment. Anticancer Drugs (2006) 0.96
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today (Barc) (2006) 0.96
Squelching glioblastoma stem cells by targeting REST for proteasomal degradation. Trends Neurosci (2009) 0.95